Polycystic ovary syndrome Based on Rotterdam Criteria. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group :Treatment of women with polycystic ovary syndrome aged 18-45 with a body mass index greater than or equal to 25, with metformin 500 mg TID for 3 months. Metformin i
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women aged 18-45 with polycystic ovary syndrome with body mass index more than 25
Exclusion criteria
Exclusion criteria: Cushing syndrome inadequately controlled thyroid disease. androgen-secreting tumor pregnancy or intention to become pregnant Breast feeding documented use of oral hormonal contraceptives and hormone-releasing implants, clomiphene citrate or estrogen modulators, gonadotropin-releasing hormone (GnRH) modulators diagnosis of diabetes and use of antidiabetic agent congenital adrenal hyperplasia due to 21-hydroxilase defficiency hyperprolactinemia, age45 year,
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of people with fasting blood sugar >/equal to 100. Timepoint: Measuring fasting blood sugar at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Fasting venous blood sampling.;Blood pressure measurement. Timepoint: Measuring blood pressure at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Sphygmomonometer.;Fasting plasma lipid level. Timepoint: Fasting plasma lipid measurement at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Fasting venous blood sampling.;Fasting plasma insulin level. Timepoint: Fasting plasma insulin level measurement at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Fasting venous blood sampling.;Fasting plasma androstenedione level. Timepoint: Fasting plasma androstenedione level measurement at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Fasting venous blood sampling.;Total plasma testosterone. Timepoint: Fasting plasma testosterone level measurement at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Fasting venous blood sampling.;C-reactive protein plasma level. Timepoint: Measuring the plasma level of C-reactive protein at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Fasting venous blood sampling.;Measurement of waist/Hip ratio. Timepoint: Measuring waist/Hip ratio at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Meter.;Body mass index. Timepoint: Measuring body mass index at the beginning of the study and after 12 weeks of using metformin or dapagliflozin. Method of measurement: Meter and scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarnaz Kamali Haghighi Shirazi
Shiraz University of Medical Sciences
Outcome results
None listed